Founder: Cyrus S. Poonawalla
Serum Institute of India Pvt. Ltd. is now the world’s largest vaccine manufacturer by a number of doses produced and sold globally (more than 1.5 billion doses) which includes Polio vaccine as well as Diphtheria, Tetanus, Pertussis, Hib, BCG, r-Hepatitis B, Measles, Mumps, and Rubella vaccines. It is estimated that about 65% of the children in the world receive at least one vaccine manufactured by Serum Institute. Vaccines manufactured by the Serum Institute are accredited by the World Health Organization, Geneva, and are being used in around 170 countries across the globe in their national immunization programs, saving millions of lives throughout the world.
Serum Institute of India is ranked as India’s No. 1 biotechnology company, manufacturing highly specialized life-saving biologicals like vaccines using cutting-edge genetic and cell-based technologies, antisera, and other medical specialties.
Serum Institute of India was founded in 1966 by Dr. Cyrus Poonawalla with the aim of manufacturing life-saving immuno-biologicals, which were in shortage in the country and imported at high prices. Thereafter, several life-saving biologicals were manufactured at prices affordable to the common man and in abundance, with the result that the country was made self-sufficient for Tetanus Anti-toxin and Anti-snake Venom serum, followed by DTP (Diphtheria, Tetanus, and Pertussis) group of Vaccines and then later on MMR (Measles, Mumps, and Rubella) group of vaccines.
The Philanthropic philosophy of the company still not only exists but has been proliferated to bring down the prices of newer vaccines such as Hepatitis-B vaccine, Combination vaccine, etc., so that not only Indian’s, but the entire underprivileged children of the world are protected from birth onwards.
Serum Institute’s entire facility is built to comply with the highest international standards. With a view to entering new markets with an expanded product portfolio, Serum Institute has achieved another milestone, that of getting US FDA compliance for its new plant manufacturing pharmaceutical Injections. The US FDA approval for this plant confirms the high level of standards infused into the manufacturing infrastructure, quality systems, training of staff, and the overall standard maintained by Serum Institute for its entire facility. This plant will be producing several liquids as well as lyophilized pharmaceutical injections for supply to the highly regulated markets of the world i.e. the USA and the EU.
Quality systems are set in a manner to comply with US FDA & MHRA requirements to provide products with the assurance of consistent quality, purity, efficacy, and safety.
The serum is prepared from the blood of normal, healthy horses. Antigenic substances are not administered to production animals for the purpose of stimulating an antibody response. Thus, the final product is referred to as normal serum.
Contains phenol and thimerosal as preservatives.
